Cytek Biosciences, Inc.

DB:8EQ Stock Report

Market Cap: €803.9m

Cytek Biosciences Future Growth

Future criteria checks 4/6

Cytek Biosciences is forecast to grow earnings and revenue by 114.8% and 11.7% per annum respectively. EPS is expected to grow by 114.8% per annum. Return on equity is forecast to be 7.9% in 3 years.

Key information

114.8%

Earnings growth rate

114.8%

EPS growth rate

Life Sciences earnings growth26.2%
Revenue growth rate11.7%
Future return on equity7.9%
Analyst coverage

Good

Last updated18 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8EQ - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202626010N/AN/A4
12/31/20252325N/AN/A6
12/31/2024205-9N/AN/A6
9/30/2024201-102933N/A
6/30/2024198-181115N/A
3/31/2024201-1216N/A
12/31/2023193-1205N/A
9/30/2023183-14-82N/A
6/30/2023176-6-11-1N/A
3/31/2023166-2-17-8N/A
12/31/20221642-22-12N/A
9/30/2022155-1-18-13N/A
6/30/2022148-3-9-4N/A
3/31/2022139-2-31N/A
12/31/2021128005N/A
9/30/20211201811N/A
6/30/20211102912N/A
3/31/20219941416N/A
12/31/20209331415N/A
12/31/201958-17-15-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8EQ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 8EQ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 8EQ is expected to become profitable in the next 3 years.

Revenue vs Market: 8EQ's revenue (11.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 8EQ's revenue (11.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 8EQ's Return on Equity is forecast to be low in 3 years time (7.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y